Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | NNMT | P40261 | 2/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020150 | 0.81 | HCAR3 (0.46) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL7940302 | 0.79 | HCAR3 (0.44) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL479854 | 0.79 | NNMT (0.47) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL1570177 | 0.79 | HCAR3 (0.48) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL15762384 | 0.79 | HCAR3 (0.44) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL12881954 | 0.78 | HCAR3 (0.43) | HCAR3NNMTCPB2KDM4ERAB9A | |
| SCHEMBL21503537 | 0.76 | CPB2 (0.49) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL20667440 | 0.76 | HCAR3 (0.42) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL20037450 | 0.76 | HCAR3 (0.46) | HCAR3NNMTCPB2CYP11B1CYP11B2 | |
| SCHEMBL12867094 | 0.76 | HCAR3 (0.42) | HCAR3NNMTCPB2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524881-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | claimed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | claimed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | HCAR3 2707/4885NNMT 2060/4885CPB2 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.